ArticleJournal of ultrasound2026
A lost race against time-a rare case of AL amyloidosis.
Article in Journal of ultrasound, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAmyloidosis is a rare multi-system disease that can affect the heart. Recent advances have been made in finding successful treatments for these patients. Nonetheless, cardiac amyloidosis continues to carry high morbidity and mortality. CASE PRESENTATION: This case refers to a 52-year-old man presenting with signs and symptoms of heart failure. Electrocardiogram showed q waves in V1-V3 and T wave inversion in the inferior and lateral leads. Echocardiography revealed moderate concentric left ventricular hypertrophy, with preserved biventricular systolic function and no other changes. Cardiac magnetic resonance showed severe left ventricular hypertrophy and diffuse fibrosis, suggesting infiltrative cardiomyopathy. Given these findings, a diagnosis of amyloidosis was considered and complementary tests were requested. Laboratory tests showed elevation of Kappa light chains in urine, with normal serum light chains. Cardiac scintigraphy with Tec99m-DPD showed increased cardiac uptake. Genetic testing showed no clinically relevant variants in the TTR gene. Salivary gland and abdominal fat biopsy demonstrated no deposition of amyloid substance. Bone marrow evaluation demonstrated the presence of 0.8% plasma cells (99.2% clonal). Given that a high degree of suspicion remained, an endocardial biopsy was performed and immunohistochemical staining revealed deposits of kappa light chains, suggesting AL amyloidosis. However, in the course of the clinical investigation, the patient's condition progressively deteriorated. By the time AL amyloidosis was diagnosed and targeted therapy initiated, the patient was already severely debilitated, ultimately leading to a short-term fatal outcome. COMMENT: Amyloidosis, often undiagnosed early, can severely affect multiple organs, particularly the heart, leading to poor prognosis without timely intervention. In this case, AL amyloidosis, a type where plasma cells produce amyloidogenic light chains, was identified. The patient's late diagnosis led to rapid progression and treatment with chemotherapy and steroids; however, his condition deteriorated quickly, resulting in a fatal outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.